Jennifer L Miller

Jennifer L Miller, M.D.

Professor

Department: MD-PEDS-ENDOCRINOLOGY
Business Phone: (352) 265-7337
Business Email: jlmiller@ufl.edu

About Jennifer L Miller

Hi my name is Dr. Jennifer Miller and I am a Professor in the division of pediatric endocrinology. I graduated with my M.D. from the University of Florida in 1998, and my M.S. in Clinical Investigation from the University of Florida in 2005. I have done all of my training in pediatrics and pediatric endocrinology at the University of Florida. I specialize in the care and treatment of individuals with Prader-Willi syndrome and other genetic causes of early-onset excessive weight gain. Go gators!

Accomplishments

Castle Connolly Regional Top Doctors
2018 · peer nomination, extensive research and careful review and screening by our doctor-directed research team
Customeer Service Key Award
2017 · Shands Hospital
Customer Service Key Award
2016 · Shands Hospital
Patient's Choice Award
2014-2018 · National Award
Compassionate Doctor Award
2011-2018 · National Award

Teaching Profile

Courses Taught
2018
MDC7400 Pediatric Clerkship

Clinical Profile

Specialties
  • Pediatrics
Subspecialties
  • Pediatric Endocrinology
Areas of Interest
  • Diabetes
  • Diabetes – resources
  • High blood pressure – children
  • Obesity in children
  • Pediatric pituitary and skull base services
  • Prader-Willi syndrome

Research Profile

My research focuses on investigation of the etiology and possible treatment for obesity and metabolic abnormalities in individuals with Prader-Willi syndrome and early-onset obesity. I have been working towards achieving an appropriate treatment for hyperphagia for the past 12 years. I currently follow over 500 patients with Prader-Willi syndrome from around the world, and over 100 patients with early-onset obesity due to other genetic causes. I am working on clinical treatment trials to treat hyperphagia in individuals with Prader-Willi syndrome and early-onset obesity..

Open Researcher and Contributor ID (ORCID)

0000-0003-4370-3438

Publications

2023
Diazoxide Choline Extended-Release Tablet in People with Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial
The Journal of Clinical Endocrinology & Metabolism. [DOI] 10.1210/clinem/dgad014.
2022
Critical review of bariatric surgical outcomes in patients with Prader-Willi syndrome and other hyperphagic disorders.
Obesity (Silver Spring, Md.). 30(5):973-981 [DOI] 10.1002/oby.23385. [PMID] 35416416.
2022
Molecular Classes and Growth Hormone Treatment Effects on Behavior and Emotion in Patients with Prader-Willi Syndrome.
Journal of clinical medicine. 11(9) [DOI] 10.3390/jcm11092572. [PMID] 35566699.
2022
The Efficacy, Safety, and Pharmacology of a Ghrelin O-Acyltransferase Inhibitor for the Treatment of Prader-Willi Syndrome.
The Journal of clinical endocrinology and metabolism. 107(6):e2373-e2380 [DOI] 10.1210/clinem/dgac105. [PMID] 35213714.
2022
Thrombosis Risk History and D-dimer Levels in Asymptomatic Individuals with Prader-Willi Syndrome.
Journal of clinical medicine. 11(7) [DOI] 10.3390/jcm11072040. [PMID] 35407648.
2021
Adults with Prader-Willi syndrome exhibit a unique microbiota profile.
BMC research notes. 14(1) [DOI] 10.1186/s13104-021-05470-6. [PMID] 33549146.
2021
Evaluating Sleep Disturbances in Children With Rare Genetic Neurodevelopmental Syndromes
Pediatric Neurology. 123:30-37 [DOI] 10.1016/j.pediatrneurol.2021.07.009. [PMID] 34388423.
2021
Hypogonadism in Adult Males with Prader-Willi Syndrome-Clinical Recommendations Based on a Dutch Cohort Study, Review of the Literature and an International Expert Panel Discussion.
Journal of clinical medicine. 10(19) [DOI] 10.3390/jcm10194361. [PMID] 34640379.
2021
Hypogonadism in Women with Prader-Willi Syndrome-Clinical Recommendations Based on a Dutch Cohort Study, Review of the Literature and an International Expert Panel Discussion.
Journal of clinical medicine. 10(24) [DOI] 10.3390/jcm10245781. [PMID] 34945077.
2021
Incidence of strabismus, strabismus surgeries, and other vision conditions in Prader-Willi syndrome: data from the Global Prader-Willi Syndrome Registry.
BMC ophthalmology. 21(1) [DOI] 10.1186/s12886-021-02057-4. [PMID] 34380467.
2021
Influence of molecular classes and growth hormone treatment on growth and dysmorphology in Prader-Willi syndrome: A multicenter study.
Clinical genetics. 100(1):29-39 [DOI] 10.1111/cge.13947. [PMID] 33615449.
2020
Dietary Management for Adolescents with Prader-Willi Syndrome.
Adolescent health, medicine and therapeutics. 11:113-118 [DOI] 10.2147/AHMT.S214893. [PMID] 32922110.
2020
Microbiota profile and efficacy of probiotic supplementation on laxation in adults affected by Prader-Willi Syndrome: A randomized, double-blind, crossover trial.
Molecular genetics & genomic medicine. 8(12) [DOI] 10.1002/mgg3.1535. [PMID] 33103385.
2019
A multidisciplinary approach to the clinical management of Prader-Willi syndrome.
Molecular genetics & genomic medicine. 7(3) [DOI] 10.1002/mgg3.514. [PMID] 30697974.
2019
Birth seasonality studies in a large Prader-Willi syndrome cohort.
American journal of medical genetics. Part A. 179(8):1531-1534 [DOI] 10.1002/ajmg.a.61263. [PMID] 31225937.
2019
Early Diagnosis in Prader-Willi Syndrome Reduces Obesity and Associated Co-Morbidities.
Genes. 10(11) [DOI] 10.3390/genes10110898. [PMID] 31698873.
2019
Molecular genetic classification in Prader-Willi syndrome: a multisite cohort study.
Journal of medical genetics. 56(3):149-153 [DOI] 10.1136/jmedgenet-2018-105301. [PMID] 29730598.
2019
Prader-Willi Syndrome – Clinical Genetics, Diagnosis and Treatment Approaches: An Update.
Current pediatric reviews. 15(4):207-244 [DOI] 10.2174/1573396315666190716120925. [PMID] 31333129.
2018
Hormonal, metabolic and skeletal phenotype of Schaaf-Yang syndrome: a comparison to Prader-Willi syndrome.
Journal of medical genetics. 55(5):307-315 [DOI] 10.1136/jmedgenet-2017-105024. [PMID] 29496979.
2018
Multicentre study of maternal and neonatal outcomes in individuals with Prader-Willi syndrome.
Journal of medical genetics. 55(9):594-598 [DOI] 10.1136/jmedgenet-2017-105118. [PMID] 29776967.
2018
Oxytocin and Naltrexone Successfully Treat Hypothalamic Obesity in a Boy Post-Craniopharyngioma Resection.
The Journal of clinical endocrinology and metabolism. 103(2):370-375 [DOI] 10.1210/jc.2017-02080. [PMID] 29220529.
2018
The effects of Bifidobacterium animalis ssp. lactis B94 on gastrointestinal wellness in adults with Prader-Willi syndrome: study protocol for a randomized controlled trial.
Trials. 19(1) [DOI] 10.1186/s13063-018-2648-x. [PMID] 29703235.
2017
Oxytocin treatment in children with Prader–Willi syndrome: A double‐blind, placebo‐controlled, crossover study
American Journal of Medical Genetics Part A. 173(5):1243-1250 [DOI] 10.1002/ajmg.a.38160. [PMID] 28371242.
2016
Elevated plasma oxytocin levels in children with Prader-Willi syndrome compared with healthy unrelated siblings.
American journal of medical genetics. Part A. 170(3):594-601 [DOI] 10.1002/ajmg.a.37488. [PMID] 26615966.
2016
Growth Charts for Prader-Willi Syndrome During Growth Hormone Treatment.
Clinical pediatrics. 55(10):957-74 [DOI] 10.1177/0009922815617973. [PMID] 26842920.
2016
Higher plasma orexin A levels in children with Prader-Willi syndrome compared with healthy unrelated sibling controls.
American journal of medical genetics. Part A. 170(8):2097-102 [DOI] 10.1002/ajmg.a.37749. [PMID] 27214028.
2016
Higher plasma orexin a levels in children with Prader-Willi syndrome compared with healthy unrelated sibling controls.
American journal of medical genetics. Part A. 170(9):2328-33 [DOI] 10.1002/ajmg.a.37777. [PMID] 27518917.
2016
The High Direct Medical Costs of Prader-Willi Syndrome.
The Journal of pediatrics. 175:137-43 [DOI] 10.1016/j.jpeds.2016.05.018. [PMID] 27283463.
2015
Growth charts for non-growth hormone treated Prader-Willi syndrome.
Pediatrics. 135(1):e126-35 [DOI] 10.1542/peds.2014-1711. [PMID] 25489013.
2015
Hyperghrelinemia in Prader-Willi syndrome begins in early infancy long before the onset of hyperphagia.
American journal of medical genetics. Part A. 167A(1):69-79 [DOI] 10.1002/ajmg.a.36810. [PMID] 25355237.
2015
Laparoscopic sleeve gastrectomy in 108 obese children and adolescents ages 5 to 21 years by Alqahtani AR, Antonisamy B, Alamri H, Elahmedi M, Zimmerman VA.
Annals of surgery. 261(4) [DOI] 10.1097/SLA.0b013e3182a7187c. [PMID] 24045441.
2015
Medication Trials for Hyperphagia and Food-Related Behaviors in Prader-Willi Syndrome.
Diseases (Basel, Switzerland). 3(2):78-85 [DOI] 10.3390/diseases3020078. [PMID] 28943610.
2015
The neurobiological drive for overeating implicated in Prader-Willi syndrome.
Brain research. 1620:72-80 [DOI] 10.1016/j.brainres.2015.05.008. [PMID] 25998539.
2014
An open-label pilot study of N-acetylcysteine for skin-picking in Prader-Willi syndrome.
American journal of medical genetics. Part A. 164A(2):421-4 [DOI] 10.1002/ajmg.a.36306. [PMID] 24311388.
2014
Effects of metformin in children and adolescents with Prader-Willi syndrome and early-onset morbid obesity: a pilot study.
Journal of pediatric endocrinology & metabolism : JPEM. 27(1-2):23-9 [DOI] 10.1515/jpem-2013-0116. [PMID] 23893676.
2014
Frequency of Prader-Willi syndrome in births conceived via assisted reproductive technology.
Genetics in medicine : official journal of the American College of Medical Genetics. 16(2):164-9 [DOI] 10.1038/gim.2013.97. [PMID] 23928912.
2014
Hypoglycemia in Prader-Willi syndrome.
American journal of medical genetics. Part A. 164A(5):1127-9 [DOI] 10.1002/ajmg.a.36405. [PMID] 24458695.
2014
Morbidity of total pancreatectomy with islet cell auto-transplantation compared to total pancreatectomy alone.
HPB : the official journal of the International Hepato Pancreato Biliary Association. 16(6):522-7 [DOI] 10.1111/hpb.12168. [PMID] 23992021.
2014
Perioperative outcomes of pancreaticoduodenectomy compared to total pancreatectomy for neoplasia.
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 18(3):549-54 [DOI] 10.1007/s11605-013-2393-0. [PMID] 24165872.
2013
Altered functional brain networks in Prader-Willi syndrome.
NMR in biomedicine. 26(6):622-9 [DOI] 10.1002/nbm.2900. [PMID] 23335390.
2013
Loss-of-function mutations in SIM1 contribute to obesity and Prader-Willi-like features.
The Journal of clinical investigation. 123(7):3037-41 [DOI] 10.1172/JCI68035. [PMID] 23778136.
2013
Prader-Willi Syndrome and Sleep-Disordered Breathing
Pediatric Annals. 42(10):200-204 [DOI] 10.3928/00904481-20130924-10. [PMID] 24126982.
2012
Approach to the child with prader-willi syndrome.
The Journal of clinical endocrinology and metabolism. 97(11):3837-44 [DOI] 10.1210/jc.2012-2543. [PMID] 23129592.
2012
Letter to the editor: Long-term experience with duodenal switch in adolescents.
Obesity surgery. 22(3):517-8 [DOI] 10.1007/s11695-011-0502-2. [PMID] 21874367.
2012
Prader-Willi syndrome.
Genetics in medicine : official journal of the American College of Medical Genetics. 14(1):10-26 [DOI] 10.1038/gim.0b013e31822bead0. [PMID] 22237428.
2012
Unique and atypical deletions in Prader-Willi syndrome reveal distinct phenotypes.
European journal of human genetics : EJHG. 20(3):283-90 [DOI] 10.1038/ejhg.2011.187. [PMID] 22045295.
2011
Carnitine and coenzyme Q10 levels in individuals with Prader-Willi syndrome.
American journal of medical genetics. Part A. 155A(3):569-73 [DOI] 10.1002/ajmg.a.33887. [PMID] 21337696.
2011
Nutritional phases in Prader-Willi syndrome.
American journal of medical genetics. Part A. 155A(5):1040-9 [DOI] 10.1002/ajmg.a.33951. [PMID] 21465655.
2009
“Efficacy of laparoscopic sleeve gastrectomy as a stand-alone technique for children with morbid obesity” and “BioEnterics intragastric balloon for treatment of morbid obesity in Prader-Willi syndrome: specific risks and benefits”.
Obesity surgery. 19(5):671-2; author reply 673 [DOI] 10.1007/s11695-008-9742-1. [PMID] 18982398.
2009
Early childhood obesity is associated with compromised cerebellar development.
Developmental neuropsychology. 34(3):272-83 [DOI] 10.1080/87565640802530961. [PMID] 19437203.
2009
Sleep disordered breathing in infants with Prader-Willi syndrome during the first 6 weeks of growth hormone therapy: a pilot study.
Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 5(5):448-53 [PMID] 19961030.
2008
Pituitary abnormalities in Prader-Willi syndrome and early onset morbid obesity.
American journal of medical genetics. Part A. 146A(5):570-7 [PMID] 17431897.
2008
Potency and fate specification in CNS stem cell populations in vitro.
Cell stem cell. 3(6):670-80 [DOI] 10.1016/j.stem.2008.09.012. [PMID] 19041783.
2007
Enhanced activation of reward mediating prefrontal regions in response to food stimuli in Prader-Willi syndrome.
Journal of neurology, neurosurgery, and psychiatry. 78(6):615-9 [PMID] 17158560.
2007
Intracranial abnormalities detected by three-dimensional magnetic resonance imaging in Prader-Willi syndrome.
American journal of medical genetics. Part A. 143A(5):476-83 [PMID] 17103438.
2007
Management approaches for pediatric obesity.
Nature clinical practice. Endocrinology & metabolism. 3(12):810-8 [PMID] 18026159.
2007
Sylvian fissure morphology in Prader-Willi syndrome and early-onset morbid obesity.
Genetics in medicine : official journal of the American College of Medical Genetics. 9(8):536-43 [PMID] 17700392.
2006
Central hypothyroidism with oxcarbazepine therapy.
Pediatric neurology. 34(3):242-4 [PMID] 16504798.
2006
Short-term effects of growth hormone on sleep abnormalities in Prader-Willi syndrome.
The Journal of clinical endocrinology and metabolism. 91(2):413-7 [PMID] 16317059.
2006
The treatment of type 2 diabetes mellitus in youth : which therapies?
Treatments in endocrinology. 5(4):201-10 [PMID] 16878999.
2005
The management of type 2 diabetes mellitus in children and adolescents.
Journal of pediatric endocrinology & metabolism : JPEM. 18(2):111-23 [PMID] 15751600.

Grants

Mar 2022 ACTIVE
A 2-Stage (Open-Label Run-in followed by Randomized Withdrawal), Double-Blind, Placebo-Controlled, Phase 2 Study of Setmelanotide in Patients with Specific Gene Defects in the Melanocortin-4 Receptor Pathway
Role: Principal Investigator
Funding: IQVIA via RHYTHM PHARMACEUTICALS
Dec 2021 ACTIVE
A Phase 2a Evaluation of Psilocybin (TRP-8802) Administration in Concert with Psychotherapy to Decrease Hyperphagia in Patients with Overeating Disorders
Role: Principal Investigator
Funding: TRYP THERAPEUTICS
Sep 2021 ACTIVE
A Phase 2, Open-Label 20-Week Study to Evaluate the Safety and Efficacy of Setmelanotide in Subjects with Hypothalamic Obesity
Role: Principal Investigator
Funding: ADVANCED CLINICAL LLC via RHYTHM PHARMACEUTICALS
Feb 2021 ACTIVE
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients with Prader-Willi Syndrome, Followed by an Open Label Extension
Role: Principal Investigator
Funding: PRA HEALTH SCIENCES via HARMONY BIOSCIENCES
Jul 2020 ACTIVE
An Open-Label, Long-Term Safety Study to Evaluate the Safety and Tolerability of Pitolisant in Pediatric Patients with Prader-Willi Syndrome (PWS) who Participated in Study HBS-101-CL-003
Role: Principal Investigator
Funding: PPD INVESTIGATOR SERVICES LLC via HARMONY BIOSCIENCES
Mar 2020 ACTIVE
Long Term Extension Trial of setmelanotide (RM-493) for patients who have completed a trial of setmelanotide for the treatment of obesity associated with genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway
Role: Principal Investigator
Funding: ADVANCED CLINICAL LLC via RHYTHM PHARMACEUTICALS
Mar 2020 ACTIVE
Research Supportive Service Agreement
Role: Principal Investigator
Funding: TRYP THERAPEUTICS
Apr 2019 – Mar 2020
PATH for PWS – PATH Study Investigator
Role: Principal Investigator
Funding: FOU FOR PRADER-WILLI RESEARCH
Nov 2018 – Nov 2022
Phase 3, Randomized, Double-Blind, Placebo-Controlled, 8-week Clinical Study to Assess the Efficacy, Safety, and Tolerability, of Intranasal Carbetocin (LV-101) in Prader-Willi Syndrome (PWS) with Long Term Follow-Up: CARE-PWS
Role: Principal Investigator
Funding: LEVO THERAPEUTICS
Oct 2018 ACTIVE
An Open-Label, Long-Term Safety Evaluation of Diazoxide Choline Controlled-Release Tablet in Patients with Prader-Willi Syndrome
Role: Principal Investigator
Funding: SOLENO THERAPEUTICS
Jul 2018 ACTIVE
Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients with rare genetic disorders of obesity
Role: Principal Investigator
Funding: ADVANCED CLINICAL LLC via RHYTHM PHARMACEUTICALS
Jun 2018 ACTIVE
A Randomized, Double-Blind, Placebo-Controlled Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients with Prader-Willi Syndrome
Role: Principal Investigator
Funding: SOLENO THERAPEUTICS
Dec 2017 – Dec 2022
A Phase 2 Study to Evaluate Efficacy, Safety, and Pharmacokinetics of GLWL-01 in the Treatment of Patients with Prader-Willi syndrome (PWS)
Role: Principal Investigator
Funding: ORPHAN REACH via GLWL RES
Jun 2017 – May 2019
Evaluating Factors that may affect the Efficacy of Intranasal Oxytocin Treatment in PWS
Role: Principal Investigator
Funding: FOU FOR PRADER-WILLI RESEARCH
Jun 2017 – May 2019
Phase 2 Study: Intranasal Oxytocin for Treatment of Infants and Children with Prader-Willi Syndrome in Nutritional Phase 1a
Role: Principal Investigator
Funding: PRADER-WILLI SYNDROME ASSO
Sep 2016 – Sep 2021
Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers
Role: Principal Investigator
Funding: RHYTHM PHARMACEUTICALS
Jul 2015 – Jun 2020
Prader-Willi Syndrome Research Fund
Role: Principal Investigator
Funding: UF FOUNDATION
Feb 2015 – Dec 2020
T+?a Marie DeFelice Prader-Willi Syndrome Research Fund
Role: Principal Investigator
Funding: UF FOUNDATION
Dec 2014 – Dec 2017
Randomized, Double-Blind, Pacebo-Controlled, Phase 3 Trial of ZGN-440 (Subcutaneous Beloranib in Suspension) in Obese Subjects with Prader-Willi Syndrome to Evaluate Total Body Fat Mass, Food-related Behavior and Safety over 6 Months
Role: Principal Investigator
Funding: ZAFGEN
Nov 2014 – Nov 2017
A Phase 2 Randomized Double-Blind Placebo-controlled Pilot Study to Assess the Effects of RM-493 a Melanocortin 4 Receptor (MC4R) Agonist in Obese Subjects with Prader-Willi Syndrome (PWS) on Safety Weight Reduction and Food-Related Behaviors
Role: Principal Investigator
Funding: RHYTHM PHARMACEUTICALS
Nov 2014 – Nov 2017
A Phase 2, Randomized, Double-Blind Placebo-controlled Pilot Study to Assess the Effects of RM-493, a Melanocortin 4 Receptor Agonist in Obese Subjects with Prader-Willi Syndrome on Safety, Weight Reduction, and Food-Related Behaviors
Role: Principal Investigator
Funding: RHYTHM PHARMACEUTICALS
Feb 2014 ACTIVE
214 OPERATION ACCOUNT
Role: Principal Investigator
Funding: 214 OPERATING ACCOUNT

Education

Master of Clinical Investigation
2003-2005 · University of Florida
Pediatric Endocrinology Fellowship
2001-2004 · University of Florida
Pediatric Residency
1998-2001 · University of Florida
Medical Doctor
1994-1998 · University of Florida
Bachelor of Science
1990-1994 · Emory University
Master of Science
1990-1994 · Emory University

Contact Details

Phones:
Business:
(352) 265-7337
Emails:
Business:
jlmiller@ufl.edu
Addresses:
Business Mailing:
DEPARTMENT OF PEDIATRICS
PO BOX 100296
JENNIFER MILLER
GAINESVILLE FL 326100296
Business Street:
PO Box 100296
GAINESVILLE FL 32610